Drug Trial Radar · NCT04219007
Vosoritide for Selected Genetic Causes of Short Stature
Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
56
Actual
Start
Aug 4, 2020
Primary completion
Aug 14, 2025
Study completion Jun 1, 2035
Sponsor
- Lead sponsor
- Andrew DauberAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Short stature can be caused by a number of genetic etiologies, many of which directly affect the growth plate. The FGFR3/CNP pathway is central to growth of the chondrocyte. The study team hypothesizes that patients with selected genetic causes of short stature that interact with this pathway will benefit from treatment with vosoritide, a CNP analog, a selective NPR-B agonist which directly targets the growth plate. This study will enroll patients with short stature in selected genetic categories and will follow them for a 6 month observation period to obtain a baseline growth velocity, safety profile and quality of life assessment. Patients will then be treated with vosoritide for 12 months and will be assessed for safety monitoring and improvement in height outcomes.
Conditions
- Short Stature
Interventions
VosoritideDrug
After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]Time frame: 12 months
- Incidence of Symptomatic Hypotension events [Safety and Tolerability]Time frame: 12 months
- Change from Baseline in annualized growth velocityTime frame: 12 months
- Change from Baseline in standardized height SDSTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's National Hospital
Washington D.C., District of Columbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.